Clinical Trials
94 trialsDonor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Institutes of Health Clinical Center (CC)
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Stanford University
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Masonic Cancer Center, University of Minnesota
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Institutes of Health Clinical Center (CC)
TAR
Baylor College of Medicine
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Roswell Park Cancer Institute
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Roswell Park Cancer Institute
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Wake Forest University Health Sciences
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences